Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $50.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by Wedbush from $48.00 to $50.00 in a research report report published on Tuesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other brokerages also recently issued reports on KNSA. TD Cowen started coverage on Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They issued a “buy” rating and a $60.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.33.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $37.92 on Tuesday. The firm has a market capitalization of $2.87 billion, a P/E ratio of 84.27 and a beta of 0.04. Kiniksa Pharmaceuticals International has a 52-week low of $18.12 and a 52-week high of $44.42. The company’s 50 day simple moving average is $41.33 and its 200-day simple moving average is $36.61.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same period in the prior year, the business posted ($0.18) EPS. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. Sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 50,490 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, October 20th. The shares were sold at an average price of $38.87, for a total value of $1,962,546.30. Following the completion of the sale, the chief accounting officer owned 27,046 shares of the company’s stock, valued at approximately $1,051,278.02. The trade was a 65.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Barry D. Quart sold 20,129 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.51, for a total transaction of $835,554.79. Following the completion of the sale, the director owned 12,546 shares of the company’s stock, valued at $520,784.46. This represents a 61.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 510,689 shares of company stock worth $20,009,290 in the last ninety days. Company insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $31,000. USA Financial Formulas bought a new position in shares of Kiniksa Pharmaceuticals International in the third quarter valued at approximately $32,000. Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $43,000. Finally, Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth $44,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.